SCHEMBL3555334

SCHEMBL3555334

CCCc1ccc(S(=O)(=O)Nc2ccc(CCc3cccc(C(=O)O)c3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KAT6A Q92794 1/20 0.56
SLC16A3 O15427 2/20 0.55
POLB P06746 1/20 0.54
METAP2 P50579 1/20 0.54
ALDH1A1 P00352 3/20 0.53
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
MAPT P10636 1/20 0.50
ATM Q13315 1/20 0.50
NR1I2 O75469 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
FFAR1 O14842 1/20 0.49
FFAR4 Q5NUL3 1/20 0.49
KEAP1 Q14145 1/20 0.48
NFE2L2 Q16236 1/20 0.48
WDR5 P61964 1/20 0.48
LIMK1 P53667 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3555360 0.93 FFAR1 (0.59) SLC16A3POLBMETAP2ALDH1A1MEN1
SCHEMBL3555180 0.93 ALDH1A1 (0.57) KAT6ASLC16A3POLBALDH1A1MEN1
SCHEMBL3556522 0.91 SLC16A3 (0.58) SLC16A3POLBALDH1A1MEN1KMT2A
SCHEMBL3554962 0.91 ALDH1A1 (0.64) SLC16A3POLBALDH1A1MEN1KMT2A
SCHEMBL3552742 0.90 MEN1 (0.63) SLC16A3POLBMEN1KMT2A
SCHEMBL3554909 0.89 CA12 (0.60) SLC16A3POLBALDH1A1MEN1KMT2A
SCHEMBL31681336 0.89 POLB (0.69) POLBMETAP2ALDH1A1MEN1KMT2A
SCHEMBL3553517 0.88 MEN1 (0.57) SLC16A3POLBALDH1A1MEN1KMT2A
SCHEMBL3554243 0.88 MEN1 (0.60) KAT6ASLC16A3POLBALDH1A1MEN1
SCHEMBL3562814 0.88 SLC16A3 (0.71) SLC16A3POLBALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US claimed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US claimed
US-7816397-B2 Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes MERCK PATENT GMBH (DE) 2010-10-19 US disclosed
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes MERCK PATENT GMBH (DE) 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045483-A1 Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes SLC5A1, ALDH7A1, ASS1 KAT6A 4632/4885SLC16A3 425/4885POLB 3962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.